Feed CCCC
CC

C4 Therapeutics, Inc.

CCCC · NASDAQ

$3.39 -1.74% (-$0.06)
1M -15.14%
Market Cap $377.6M
P/E Ratio -
Div. Yield -
ROE 45.45%
Piotroski F-Score Weak
3/9
Valuation
50 /100
Fair
P/S 10.78x
P/B 1.53x
P/E N/A
Growth
36 /100
Stable
Rev. growth 4.95%
Book val. growth 3.91%
EPS growth N/A
Profitability
20 /100
Weak
Gross margin 94.86%
Net margin 289.44%
Op. margin 318.97%
Quality
1 /100
Poor
ROIC 35.21%
ROE 45.45%
ROA 28.22%
Debt
100 /100
Low
Debt/Equity 0.23x
Current ratio 5.45x
Int. coverage N/A
Stability
25 /100
Unstable
Beta 2.95x
Rev. volatility 53.38%
EPS volatility 22.62%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o CCCC
Online

O podjetju

C4 Therapeutics, Inc. (CCCC) is a biotechnology company focused on developing novel therapeutics based on protein degradation technology. Their platform enables the creation of small molecules that bind to target proteins and induce their selective degradation. This innovative therapeutic strategy has the potential to treat a wide range of diseases, including cancer and neurodegenerative disorders. C4 Therapeutics collaborates with major pharmaceutical companies to develop and commercialize new drug candidates. Their goal is to bring innovative treatment options to patients with various diseases. Shares of C4 Therapeutics, Inc. (CCCC) may be an attractive investment opportunity for investors interested in advanced therapeutic technologies and the biotechnology sector.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Andrew J. Hirsch

Employees

104

Headquarters

Watertown

Prihajajoči dogodki

05 NOV.

Earnings

Upcoming earnings report

47d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.